Literature DB >> 32875573

Models to predict disease-free survival for hepatocellular carcinoma patients with surgical resections.

Yin Lai1, Jin-Chiao Lee2, Hao-Chien Hung2, Chih-Hsien Cheng2, Tsung-Han Wu2, Chen-Fang Lee2, Ting-Jung Wu2, Hong-Shiue Chou2, Kun-Ming Chan2, Wei-Chen Lee2.   

Abstract

BACKGROUND AND OBJECTIVES: Precise prognostic prediction for an individual hepatocellular carcinoma (HCC) patient before and after liver resection is important. We aimed to establish simple prognostic models to predict disease-free survival (DFS) for these patients.
METHODS: Six hundred and ninety-eight HCC patients with liver resections were reviewed. Preoperative (model 1) and postoperative (model 2) nomogram-based scoring systems were constructed by multivariate analyses, and DFS was estimated.
RESULTS: Among 698 patients, 490 (70.2%) patients had tumor recurrence at a median follow-up of 84.4 months. Risk factors of tumor recurrence in model 1 included viral hepatitis, platelet count, albumin, indocyanine green retention rate, multiplicity of tumor, and radiologic total tumor volume (TTV). Prognostic variables identified in model 2 were viral hepatitis, platelet count, multiplicity of tumor, cirrhosis, microvascular invasion, and pathologic TTV. By nomogram in model 1, the patients were classified into three groups with 5-year DFS of 61.0%, 35.7%, and 21.1%, respectively (P < .0001). In model 2, the patients were divided into five groups with 5-year DFS of 58.0%, 43.7%, 24.0%, 15.4%, and 0.0%, respectively (P < .0001).
CONCLUSION: Based on nomogram models, DFS for the patients who had liver resection for HCC can be predicted before liver resection and re-assessed after liver resection.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  hepatocellular carcinoma; nomogram; prediction; tumor recurrence

Mesh:

Year:  2020        PMID: 32875573     DOI: 10.1002/jso.26169

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  1 in total

1.  Modified preoperative score to predict disease-free survival for hepatocellular carcinoma patients with surgical resections.

Authors:  Yin Lai; Jin-Chiao Lee; Hao-Chien Hung; Yu-Chao Wang; Chih-Hsien Cheng; Tsung-Han Wu; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Kun-Ming Chan; Chen-Yao Kao; Wei-Chen Lee
Journal:  World J Hepatol       Date:  2022-09-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.